About Neurimmune
With its Reverse Translational Medicine™ technology platform, Neurimmune translates the genetic information obtained from white blood cells from elderly human donors into therapeutic antibodies. These antibodies can have unique pharmacological activities combined with high affinity, target selectivity, excellent pharmacodynamics and low immunogenicity.
Neurimmune licensed its antibody Aducanumab for the treatment and prevention of Alzheimer’s disease to Biogen in 2007, and collaborates with Biogen on its development. Aducanumab is a recombinant human monoclonal antibody targeting Abeta aggregates that are thought to play a role in the neurodegenerative process in Alzheimer’s disease. Neurimmune and Biogen extended their collaboration in 2010. Biogen acquired exclusive rights to Neurimmune's antibodies against alpha-synuclein, tau and TDP-43. These proteins are thought to play central roles in Parkinson’s disease, taupoathies, ALS and fronto-temporal dementia.
Quote
« At Neurimmune, we focus on CNS and protein aggregation diseases including Alzheimer’s and Parkinson’s diseases, amyotrophic lateral sclerosis and dementia with Lewy bodies.»
In 2016, Neurimmune and Biogen further extended their collaboration by adding Neurimmune's antibody programs on C9orf72 for the treatment of ALS and fronto-temporal dementia.
Neurimmune's antibodies against SOD1 for the treatment of ALS and antibodies against ATTR for the treatment of ATTR cardiomyopathy are in early clinical development. Neurimmune also expanded its pipeline to other treatment modalities and develops a small molecule program on M1 AChR activation, and gene therapy programs on vectorized human antibodies.
Quote
« Neurimmune's team of scientists and clinical experts is committed to delivering innovative therapies by focusing on science-driven discoveries.»
